Stockholders’ Equity |
9 Months Ended |
|---|---|
Sep. 30, 2026 | |
| Equity [Abstract] | |
| Stockholders’ Equity | Note 8 –Stockholders’ Equity
Omnibus Incentive Plan
Stock Options
Stock-based compensation expense is reflected in selling, general and administrative expenses in the accompanying condensed statements of operations and was $ million and $ million during the three months ended September 30, 2026 and 2025, respectively, and $ million and $ million during the nine months ended September 30, 2026 and 2025, respectively. As of September 30, 2026, there was $ million of unrecognized stock-based compensation expense related to outstanding stock options that will be recognized over the weighted average remaining vesting period of years.
There were options granted during the three and nine months ended September 30, 2026. There were options granted during the three months ended September 30, 2025 and options granted during the nine months ended September 30, 2025 in connection with entering into certain employment and consulting agreements.
There were options exercised during the three and nine months ended September 30, 2026 and 2025.
There were and option grants forfeited during the three and nine months ended September 30, 2026, respectively. There were option grants forfeited during the three months ended September 30, 2025 and there were option grants forfeited during the nine months ended September 30, 2025.
Warrants
There were warrants issued during the three and nine months ended September 30, 2026 and 2025.
Pre-funded warrants issued in 2021 were exercised for 25,972 shares of common stock during the three months ended September 30, 2025, at an exercise price of $0.0001 per share. Pre-funded warrants issued in 2023 and 2021 were exercised for 74,862 shares of common stock during the nine months ended September 30, 2025, at an exercise price of $0.0001 per share.
There were warrants that expired during the three months ended September 30, 2026. There were warrants exercisable for shares of common stock that expired during the three months ended September 30, 2025. There were warrants exercisable for and shares of common stock that expired during the nine months ended September 30, 2026 and 2025, respectively.
Warrants issued in 2024 were exercised for shares of common stock during the three and nine months ended September 30, 2025, at an exercise price of $140.875 per share.
A warrant issued in 2021 was exercised during the three and nine months ended September 30, 2025, at an exercise price of $245.00 per share.
Equity Issuances
There were approximately and shares of common stock issued during the three and nine months ended September 30, 2026, respectively, under our at-the-market equity program resulting in proceeds of $0.2 million and $0.3 million during the three and nine months ended September 30, 2026, respectively, net of transaction fees.
|